Belgian Study Tests Digital Monitoring System for Oral Therapy Adherence in Non-Hodgkin Lymphoma — Implications for Australian Practice

References

1. 1.Grand Hôpital de Charleroi. (2024). AI-based Predictive and Interventional System for Early Detection of Non-compliance Risks With Oral Therapies in Lymphoma Patients. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07546188
2. 2.Greer, J. A., Amoyal, N., Nisotel, L., Fishbein, J. N., MacDonald, J., Stagl, J., Lennes, I., Temel, J. S., Safren, S. A., & Pirl, W. F. (2016). A systematic review of adherence to oral antineoplastic therapies. The Oncologist, 21(12), 1511-1519. https://doi.org/10.1634/theoncologist.2016-0114
3. 3.Partridge, A. H., Avorn, J., Wang, P. S., & Winer, E. P. (2002). Adherence to therapy with oral antineoplastic agents. Journal of the National Cancer Institute, 94(9), 652-661. https://doi.org/10.1093/jnci/94.9.652
4. 4.Sehn, L. H., & Salles, G. (2021). Diffuse large B-cell lymphoma. New England Journal of Medicine, 384(9), 842-858. https://doi.org/10.1056/NEJMra2027612
5. 5.Weingart, S. N., Brown, E., Bach, P. B., Eng, K., Johnson, S. A., Kuzel, T. M., Langbaum, T. S., Leedy, R. D., Muller, R. J., Newcomer, L. N., O'Brien, S., Reinke, D., Rubino, M., Saltz, L., & Walters, R. S. (2008). NCCN Task Force Report: Oral chemotherapy. Journal of the National Comprehensive Cancer Network, 6(1), 1-14. https://doi.org/10.6004/jnccn.2008.0003